Abstract
The sociology of expectations has examined ways in which future expectations shape how technological options are selected and stabilised. Personal genomic susceptibility testing (PGST) is introduced as an example of a technology where expectations serve a crucial role, thanks to the inherently future-oriented nature of testing for genetic susceptibility to future health conditions. Nonetheless, expectations may increase rather than decrease scientific, regulatory and commercial uncertainties surrounding a technology. Technology promoters may therefore enact particular strategies to prove that technologies are not in need of stringent, technology-specific regulation. With the aid of an extensive historical analysis of company websites, together with semi-structured interviews with company representatives, it is shown how four PGST companies based in the United States have used efforts towards collaborative standardisation as ways of stabilising and legitimating PGST in an often hostile environment. We explore how these strategies make use of expectations, and how they centre on the promotion of new ‘regulatory objects’ in an effort to influence regulatory agendas. Although processes of standardisation in the PGST industry have stalled, we suggest that they nonetheless represent successful engagement with regulators, insofar as they have succeeded in shaping regulatory agendas and staving off new regulation.
Similar content being viewed by others
Notes
Some question whether this idea of personalised medicine is even coherent. See, for example, Busch (2011, p. 317, n. 16).
Some limitations of our approach should be noted. The Internet Archive does not preserve webpages from Navigenics.com, as the company website is configured to prevent ‘bots’ (automated software applications used for tasks like indexing webpages) from indexing its content. Nonetheless, the company archives its press releases online, and a number of past interviews with senior staff, together with the interviews undertaken as part of this project, were also available. 23andMe and deCODEme were unavailable for interview, citing time pressures.
References to webpages are given below in the text in the form (site, ‘page title’, date range), where the date range indicates the dates of the earliest and the most recent instances of the quoted text we found.
References
Adam, B. and Groves, C. (2007) Future Matters: Action, Knowledge, Ethics. Leiden, The Netherlands: Brill.
Bakker, S., Van Lente, H. and Meeus, M. (2011) Arenas of expectations for hydrogen technologies. Technological Forecasting and Social Change 78 (1): 152–162.
Becker, D. (2010) Testimony of David Becker to U.S. house of representatives committee on energy and commerce, 22 July, http://democrats.energycommerce.house.gov/documents/20100722/Becker.Testimony.07.22.2010.pdf, accessed 16 July 2011.
Bloss, C.S., Madlensky, L., Schork, N.J. and Topol, E.J. (2011) Genomic information as a behavioral health intervention: Can it work? Personalized Medicine 8 (6): 659–667.
Borup, M., Brown, N., Konrad, K. and van Lente, H. (2006) The sociology of expectations in science and technology. Technology Analysis & Strategic Management 18 (3–4): 285–298.
Brown, N. (2005) Shifting tenses: Reconnecting regimes of truth and hope. Configurations 13 (3): 331–355.
Busch, L. (2011) Standards: Recipes for Reality. Cambridge, MA, London: MIT Press.
Carmichael, M. (2010) DNA Dilemma: The Full Interview with the FDA on DTC Genetic Tests, [online], http://www.thedailybeast.com/newsweek/blogs/the-human-condition/2010/08/05/dna-dilemma-the-full-interview-with-the-fda-on-dtc-genetic-tests.html, accessed 12 October 2010.
Cornel, M.C. et al (2011) Genetic testing and common disorders: How to assess relevance and possibilities. European Journal of Human 19: S6–S44.
Curnutte, M. and Testa, G. (2012) Consuming genomes: Scientific and social innovation in direct-to-consumer genetic testing. New Genetics and Society 31 (2): 159–181.
de Souza, N. (2012) Genomics: The ENCODE project. Nature Methods 9 (11): 1046–1046.
Federation of European Academies of Medicine (FEAM). (2012) Direct-to-Consumer Genetic Testing for Health-Related Purposes in the European Union: The View from EASAC and FEAM. Brussels, Belgium: European Academies Science Advisory Council.
Feero, W.G., Guttmacher, A.E. and Collins, F.S. (2008) The genome gets personal – almost. JAMA: The Journal of the American Medical Association 299 (11): 1351–1352.
Fleming, N. (2008) Rival Genetic Tests Leave Buyers Confused, London: Times Newspapers, http://www.timesonline.co.uk/tol/news/science/article4692891.ece, accessed 9 June 2011.
Foster, M., Mulvihill, J. and Sharp, R. (2009) Evaluating the utility of personal genomic information. Genetics in Medicine 11 (8): 570–574.
Fraker, M. and Mazza, A.-M. (2011) Personal Genomics: Establishing the Scientific Foundation for Using Personal Genome Profiles for Risk Assessment, Health Promotion, and Disease Prevention. Washington DC: National Academies Press.
Garud, R. and Ahlstrom, D. (1997) Technology assessment: A socio-cognitive perspective. Journal of Engineering and Technology Management 14 (1): 25–48.
Goetz, T. (2007) 23AndMe will decode your DNA for $1000. Welcome to the age of genomics. Wired, [online], 17 November, http://www.wired.com/medtech/genetics/magazine/15-12/ff_genomics, accessed 15 July 2011.
Gould, A. (2010) Testimony of Ashley C. Gould, General Counsel, 23andMe, Inc. Washington DC, http://democrats.energycommerce.house.gov/documents/20100722/Gould.Testimony.07.22.2010.pdf, accessed 20 June 2011.
Grosse, S.D., McBride, C.M., Evans, J.P. and Khoury, M.J. (2009) Personal utility and genomic information: Look before you leap. Genetics in Medicine 11 (8): 575–576.
Groves, C. (2009) Nanotechnology, contingency and finitude. Nanoethics 3 (1): 1–16.
Hall, W.D., Mathews, R. and Morley, K.I. (2010) Being more realistic about the public health impact of genomic medicine. PLoS Med 7 (10): e1000347.
Hsu, A.R., Avey, L., Mountain, J.L. and Wojcicki, A. (2009) A pragmatic consideration of ethical issues relating to personal genomics. American Journal of Bioethics 9 (6–7): 1–2.
Hudson, K., Javitt, G., Burke, W. and Byers, P. (2007) ASHG statement on direct-to-consumer genetic testing in the United States. American Journal of Human Genetics 81 (3): 635–637.
International Standards Organisation (ISO). (2007) ISO/TC 229 Business Plan. Geneva, Switzerland: ISO.
Janssens, A.C.J.W., Gwinn, M., Bradley, L.A., Oostra, B.A., Van Duijn, C.M. and Khoury, M.J. (2008) A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. The American Journal of Human Genetics 82 (3): 593–599.
Khan, R. (2011) Why genetic privacy could be doomed. Gene Expression, [online], http://blogs.discovermagazine.com/gnxp/2011/06/why-genetic-privacy-could-be-doomed/, accessed 9 June 2011.
Khoury, M.J. et al (2009) The scientific foundation for personal genomics: Recommendations from a national institutes of health-centers for disease control and prevention multidisciplinary workshop. Genetics in Medicine 11 (8): 559–567.
Kutz, G. (2006) Nutrigenetic Testing: Tests Purchased from Four Web Sites Mislead Consumers. Washington DC: United States Government Accountability Office.
Kutz, G. (2010) Direct-to-Consumer Genetic Tests: Misleading Test Results are Further Complicated by Deceptive Marketing and Other Questionable Practices. Washington DC: United States Government Accountability Office.
Lezaun, J. (2006) Creating a new object of government. Social Studies of Science 36 (4): 499–531.
Lippi, G., Favaloro, E.J. and Plebani, M. (2011) Direct-to-consumer testing: More risks than opportunities. International Journal of Clinical Practice 65 (12): 1221–1229.
Liu, S. and Song, Y. (2010) Building genetic scores to predict risk of complex diseases in humans: Is it possible? Diabetes 59 (11): 2729–2731.
Loconto, A. and Busch, L. (2010) Standards, techno-economic networks, and playing fields: Performing the global market economy. Review of International Political Economy 17 (3): 507–536.
Lynch, S.N. (2008) Should genetic tests be regulated?, http://www.time.com/time/health/article/0,8599,1825539,00.html, accessed 7 June 2011.
McCarthy, M.I. et al (2008) Genome-wide association studies for complex traits: Consensus, uncertainty and challenges. Nat Rev Genet 9 (5): 356–369.
McGoey, L. (2012) Strategic unknowns: Towards a sociology of ignorance. Economy and Society 41 (1): 1–16.
McGowan, M.L., Fishman, J.R. and Lambrixa, M. (2010) Personal genomics and individual identities: Motivations and moral imperatives of early users. New Genetics and Society 29 (3): 261–290.
McGuire, A.L. and Burke, W. (2008) An unwelcome side effect of direct-to-consumer personal genome testing. JAMA: The Journal of the American Medical Association 300 (22): 2669–2671.
McGuire, A.L., Diaz, C.M., Wang, T. and Hilsenbeck, S.G. (2009) Social networkers’ attitudes toward direct-to-consumer personal genome testing. American Journal of Bioethics 9 (6–7): 3–10.
Mesko, B. (2009) Pathway genomics: Interview. ScienceRoll, [online], http://scienceroll.com/2009/11/30/pathway-genomics-interview/, accessed 16 June 2011.
Michaels, D. (2008) Manufactured uncertainty. In: R. Proctor and L.L. Schiebinger (eds.) Agnotology: The Making and Unmaking of Ignorance. Stanford, CA: Stanford University Press, pp. 90–107.
Moreira, T. and Palladino, P. (2005) Between truth and hope: On parkinson's disease, neurotransplantation and the production of the ‘self’. History of the Human Sciences 18 (3): 55–82.
Mountain, J. (2008) 23andKids: Growing up genotyped. The Spittoon, [online], http://spittoon.23andme.com/2008/10/28/23andkids-growing-up-genotyped/, accessed 1 July 2011.
Offit, K. (2008) Genomic profiles for disease risk. JAMA: The Journal of the American Medical Association 299 (11): 1353–1355.
Paynter, N.P. et al (2010) Association between a literature-based genetic risk score and cardiovascular events in women. JAMA: The Journal of the American Medical Association 303 (7): 631–637.
Porter, T.M. (1995) Trust in Numbers: The Pursuit of Objectivity in Science and Public Life. Princeton, NJ: Princeton University Press.
Rashba, E. and Gamota, D. (2003) Anticipatory standards and the commercialization of nanotechnology. Journal of Nanoparticle Research 5 (3): 401–407.
Ray, T. (2010) Navigenics agrees not to market genetic testing services directly to NY residents. GenomeWeb, [online], http://www.genomeweb.com/dxpgx/navigenics-agrees-not-market-genetic-testing-services-directly-ny-residents, accessed 10 September 2011.
Reid, R.J. et al (2012) Association between health-service use and multiplex genetic testing. Genetics in Medicine 14 (10): 852–859.
Richards, M. (2010) Reading the runes of my genome: A personal exploration of retail genetics. New Genetics and Society 29 (3): 291–310.
Secretary's Advisory Committee On Genetics, Health And Society (SACGHS). (2008) U.S. System of Oversight of Genetic Testing: A Response to the Charge of the Secretary of Health and Human Services. Bethesda, MD: Department of Health and Human Services.
Secretary's Advisory Committee On Genetics, Health And Society (SACGHS). (2010) Direct-to-Consumer Genetic Testing. Bethesda, MD: Department of Health and Human Services.
Singer, E. (2008) Q&A: Linda Avey and Anne Wojcicki. Technology Review 111 (6): 40.
Tamir, S. (2010) Direct-to-consumer genetic testing: Ethical–legal perspectives and practical considerations. Medical Law Review 18 (2): 213–238.
Tomasson, M. (2009) Legal, ethical, and conceptual bottlenecks to the development of useful genomic tests. Annals of Health Law 18 (2): 231–260.
Umbehr, J. (2008) An Interview with Navigenics, http://medgadget.com/2008/07/an_interview_with_navigenics_1.html, accessed 10 July 2011.
Vanier, V. (2010) Written Testimony of Vance Vanier, M.D., Chief Executive Officer Navigenics, Inc. [online], http://democrats.energycommerce.house.gov/documents/20100722/Vanier.Testimony.07.22.2010.pdf, accessed 20 June 2011.
Vorhaus, D. (2011) Closer scrutiny ahead for DTC genetic testing claims. Genomics Law Report, http://www.genomicslawreport.com/index.php/2011/03/24/closer-scrutiny-ahead-for-dtc-claims, accessed 16 June 2011.
Wadman, M. (2008) Gene-testing firms face legal battle. Nature 453 (7199): 1148–1149.
Warburton, E. (2008) Navigenics – The Whole Interview, http://archive.blisstree.com/feel/navigenics-the-whole-interview/, accessed 14 June 2011.
Zuk, O., Hechter, E., Sunyaev, S.R. and Lander, E.S. (2012) The mystery of missing heritability: Genetic interactions create phantom heritability. Proceedings of the National Academy of Sciences 109 (4): 1193–1198.
Acknowledgements
The authors would like to thank Dr Andrew Bartlett, Professor Lawrence Busch, Dr Joan Haran and Professor Adam Hedgecoe for helpful comments on an earlier version of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Groves, C., Tutton, R. Walking the tightrope: Expectations and standards in personal genomics. BioSocieties 8, 181–204 (2013). https://doi.org/10.1057/biosoc.2013.1
Published:
Issue Date:
DOI: https://doi.org/10.1057/biosoc.2013.1